| Recruiting | Definitive Radiation Therapy for Inoperable Breast Cancer NCT07122713 | Alexander Stessin | N/A |
| Recruiting | Effects of Chemotherapy Treatment on Metaboreflex, Mechanoreflex, and Baroreflex Function: PROTECT-08B Study NCT07069790 | Centre Paul Strauss | N/A |
| Recruiting | Personalization of External Beam Radiation Therapy in Localised Tumours NCT07047495 | European Institute of Oncology | — |
| Not Yet Recruiting | The Application Value of Spectral CT in the Accurate Staging of Breast Cancer NCT06977412 | Yunnan Cancer Hospital | N/A |
| Recruiting | A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making NCT07389408 | National and Kapodistrian University of Athens | — |
| Recruiting | Preoperative Radiation Therapy and Immediate Breast Reconstruction NCT06739655 | Cancer Research Antwerp | N/A |
| Recruiting | Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer NCT06671262 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy NCT06596018 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 / Phase 2 |
| Active Not Recruiting | Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Car NCT06805084 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Suspended | High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breas NCT06538389 | City of Hope Medical Center | Phase 2 |
| Recruiting | Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy NCT06401889 | Mayo Clinic | — |
| Active Not Recruiting | Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study NCT06234488 | Medical College of Wisconsin | — |
| Recruiting | Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan NCT06805812 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Active Not Recruiting | Explore Association Models Between Environmental Hormones andBreast Cancer NCT06765395 | Pei-Hung Liao | — |
| Recruiting | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 | Genmab | Phase 1 / Phase 2 |
| Terminated | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer NCT05447910 | Mayo Clinic | — |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer NCT05183828 | University of Washington | Phase 4 |
| Completed | Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer NCT04857697 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy NCT04769960 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Bre NCT04535323 | Mayo Clinic | Phase 1 |
| Terminated | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer NCT04139993 | Mayo Clinic | Phase 1 |
| Recruiting | Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer NCT04517838 | Mayo Clinic | — |
| Unknown | Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Pat NCT04300829 | Centre Leon Berard | Phase 3 |
| Unknown | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Resid NCT04197687 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and N NCT03094052 | University of California, San Francisco | Phase 2 |
| Withdrawn | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Can NCT03666819 | Mayo Clinic | Phase 2 |
| Terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741 | Mayo Clinic | Phase 1 |
| Terminated | Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer NCT03137693 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Completed | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast NCT03106415 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Brea NCT03250676 | Eisai Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca NCT02957968 | Virginia Commonwealth University | Phase 2 |
| Terminated | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer NCT02824575 | Montefiore Medical Center | Phase 1 |
| Active Not Recruiting | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT02453620 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer NCT02530489 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer NCT02515110 | Virginia Commonwealth University | N/A |
| Active Not Recruiting | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating NCT02488967 | NRG Oncology | Phase 3 |
| Completed | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer NCT02282345 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Can NCT02115282 | National Cancer Institute (NCI) | Phase 3 |
| Suspended | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage III NCT02037529 | Academic and Community Cancer Research United | Phase 3 |
| Unknown | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas NCT01942629 | Rambam Health Care Campus | — |
| Active Not Recruiting | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With NCT01730833 | City of Hope Medical Center | Phase 2 |
| Terminated | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Br NCT01697293 | Prescient Therapeutics, Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer NCT01245712 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple My NCT00869206 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients W NCT00433511 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node NCT00310180 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With NCT00005970 | National Cancer Institute (NCI) | Phase 3 |